Jomnarong Lertsuwan

Dr. Jomnarong Lertsuwan

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 August 2018 in Cancers
Verified
Journal Article
Open access
PDF file
JLJomnarong Lertsuwan
Jomnarong Lertsuwan
KLKornkamon Lertsuwan
Kornkamon Lertsuwan
ASAnyaporn Sawasdichai
Anyaporn Sawasdichai
NTNathapol Tasnawijitwong
Nathapol Tasnawijitwong
KLKa Ying Lee
Ka Ying Lee
JSJutamaad Satayavivad
Jutamaad Satayavivad
Cholangiocarcinoma is a disease with a poor prognosis and increasing incidence and hence there is a pressing unmet clinical need for new adjuvant treatments. Protein kinase CK2 (previously casein kinase II) is a ubiquitously expressed protein kinase that is up-regulated in multiple cancer cell types. The inhibition of CK2 activity using CX-4945 (Silmitasertib) has been proposed as a novel treatment in multiple disease settings including cholangiocarcinoma. Here, we show that CX-4945 inhibited the proliferation of cholangiocarcinoma cell lines in vitro. Moreover, CX-4945 treatment induced the formation of cytosolic vacuoles in cholangiocarcinoma cell lines and other cancer cell lines. The vacuoles contained extracellular fluid and had neutral pH, features characteristic of methuosis. In contrast, simultaneous knockdown of both the α and α′ catalytic subunits of protein kinase CK2 using small interfering RNA (siRNA) had little or no effect on the proliferation of cholangiocarcinoma cell lines and failed to induce the vacuole formation. Surprisingly, low doses of CX-4945 increased the invasive properties of cholangiocarcinoma cells due to an upregulation of matrix metallopeptidase 7 (MMP-7), while the knockdown of CK2 inhibited cell invasion. Our data suggest that CX-4945 inhibits cell proliferation and induces cell death via CK2-independent pathways. Moreover, the increase in cell invasion brought about by CX-4945 treatment suggests that this drug might increase tumor invasion in clinical settings.

16 July 2018 in BioMetals
Verified
Journal Article
Closed access
PDF file
KLKornkamon Lertsuwan
Kornkamon Lertsuwan
KNKetsaraporn Nammultriputtar
Ketsaraporn Nammultriputtar
SNSupanan Nanthawuttiphan
Supanan Nanthawuttiphan
SPSupathra Phoaubon
Supathra Phoaubon
JLJomnarong Lertsuwan
Jomnarong Lertsuwan
NCNarattaphol Charoenphandhu
Narattaphol Charoenphandhu

10 February 2017 in Anticancer Research
Verified
Journal Article
Closed access
PDF file
KLKornkamon Lertsuwan
Kornkamon Lertsuwan
WPWachen Peters
Wachen Peters
LJLindsay Johnson
Lindsay Johnson
JLJomnarong Lertsuwan
Jomnarong Lertsuwan
IMIrene Marwa
Irene Marwa
RSRobert A Sikes
Robert A Sikes
Background: Anticancer activity of extracellular nucleotides has been investigated in many types of cancer. Herein, the effects of extracellular nucleotides and the receptor profile for these nucleotides on prostate cancer (PCa) were elaborated. Materials and Methods: PCa cell lines representing different stages of PCa were used. The effects of ATP and adenosine on PCa growth and migration on different extracellular matrix proteins were examined by MTT and wound-healing assays. Purinergic receptor profiling was carried out by reverse transcription-polymerase chain reaction (RT-PCR). Results: A growth-inhibitory effect of ATP and adenosine was observed on all PCa cell lines tested. Several ATP-recognized P2 receptors and adenosine receptors were commonly expressed in PCa cell lines. Neither ATP nor adenosine had any significant effect on PCa migration. Conclusion: ATP and adenosine had an antiproliferative effect on PCa cells without affecting their motility, indicating their potential as a novel therapy for PCa.

5 July 2017 in Anticancer Research
Verified
Journal Article
Closed access
PDF file
JLJomnarong Lertsuwan
Jomnarong Lertsuwan
MRMathuros Ruchirawat
Mathuros Ruchirawat
Background/Aim: Inhibitory effects of extracellular nucleotides have been investigated in many types of cancers. Herein, we aimed to determine the effects of ATP and adenosine and their receptor profile on cholangiocarcinoma (CCA) cells. Materials and Methods: Two CCA and one immortalized cholangiocyte cell line were used. The effects of ATP and adenosine on cell proliferation and motility were examined by MTT and wound-healing/trans-well invasion assays, respectively. Purinergic receptor profiling was carried out by reverse transcription-polymerase chain reaction (RT-PCR). Results: ATP and adenosine induced proliferation-inhibitory and motility-inhibitory effects in all cell lines tested. However, immortalized cholangiocytes showed resistance in proliferation inhibition. Several P2 receptors were commonly expressed in all cells, whereas no adenosine receptor was expressed. Furthermore, no synergistic effects of ATP and adenosine were observed in CCA cells. Conclusion: ATP and adenosine had anti-proliferative and anti-motility effects in CCA cells, while there was a smaller effect on normal cholangiocytes. These data indicate the potential use of ATP and odenosine as a novel therapy for CCA.

Verified
Journal Article
Open access
PDF file
KLKornkamon Lertsuwan
Kornkamon Lertsuwan
SPSupathra Phoaubon
Supathra Phoaubon
NTNathapol Tasnawijitwong
Nathapol Tasnawijitwong
JLJomnarong Lertsuwan
Jomnarong Lertsuwan
Cholangiocarcinoma (CCA) is a lethal disease with increasing incidence worldwide. Previous study showed that CCA was sensitive to adenosine. Thereby, molecular mechanisms of CCA inhibition by adenosine were examined in this study. Our results showed that adenosine inhibited CCA cells via an uptake of adenosine through equilibrative nucleoside transporters (ENTs), instead of activation of adenosine receptors. The inhibition of ENTs by NBTI caused the inhibitory effect of adenosine to subside, while adenosine receptor antagonists, caffeine and CGS-15943, failed to do so. Intracellular adenosine level was increased after adenosine treatment. Also, a conversion of adenosine to AMP by adenosine kinase is required in this inhibition. On the other hand, inosine, which is a metabolic product of adenosine has very little inhibitory effect on CCA cells. This indicates that a conversion of adenosine to inosine may reduce adenosine inhibitory effect. Furthermore, there was no specific correlation between level of proinflammatory proteins and CCA responses to adenosine. A metabolic stable analog of adenosine, 2Cl-adenosine, exerted higher inhibition on CCA cell growth. The disturbance in intracellular AMP level also led to an activation of 5′ AMP-activated protein kinase (AMPK). Accordingly, we proposed a novel adenosine-mediated cancer cell growth and invasion suppression via a receptor-independent mechanism in CCA.

26 December 2022 in Cancers
Verified
Journal Article
Open access
PDF file
JLJomnarong Lertsuwan
Jomnarong Lertsuwan
KLKornkamon Lertsuwan
Kornkamon Lertsuwan
ASAnyaporn Sawasdichai
Anyaporn Sawasdichai
NTNathapol Tasnawijitwong
Nathapol Tasnawijitwong
KLKa Ying Lee
Ka Ying Lee
JSJutamaad Satayavivad
Jutamaad Satayavivad
Authors would like to make a correction to the previous article